Shanghai Junshi Biosciences next to test HKEX listing; With one eye on Sage, Marinus reports prelim PPD data
→ The new rule allowing biotechs to list on the Hong Kong exchange before recording revenue or profit has attracted a mixed bag of performers …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
